Drugs / BCMA CAR-T cells
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT04186052 | Mar 2019 → Mar 2021 | plasma cell myeloma | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Unknown | No outcome recorded |
| Phase 0 | NCT03661554 | Apr → Oct 2018 | refractory plasma cell neoplasm | The Pregene (ShenZhen) Biotechnology Company, Ltd. | Unknown | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT05740891 | Mar 2023 → Mar 2025 | plasma cell myeloma | Zhejiang University | Unknown | No outcome recorded |
| Phase 1 | NCT04795882 | Apr 2022 → Mar 2029 expected | plasma cell myeloma | University College, London | Recruiting | No outcome recorded |
| Phase 1 | NCT04194931 | Dec 2019 → Dec 2020 | refractory plasma cell neoplasm | The First Affiliated Hospital of Nanchang University | Unknown | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT05150522 | Jul 2021 → Jul 2024 | plasma cell myeloma | Shenzhen University General Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT04846439 | Apr 2021 → Mar 2023 | acute leukemia, blood platelet disease | The First Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04272151 | Dec 2019 → Dec 2023 | plasma cell myeloma | Chongqing Precision Biotech Co., Ltd | Unknown | No outcome recorded |
| Phase 1/2 | NCT04271644 | Apr 2019 → Dec 2026 expected | plasma cell myeloma | Chongqing Precision Biotech Co., Ltd | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05712083 | Jan 2023 → Apr 2024 | plasma cell myeloma | Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCMA CAR-T cells | “Sequential infusion of CD19 and BCMA CAR-T cells” NCT04846439 ↗ |
| Action | Deplete | “so that T lymphocytes can selectively kill B lymphocyte-derived tumor cells.” NCT03661554 ↗ |
| Modality | Cell therapy | “BCMA nano-antibody CAR-T cells” NCT03661554 ↗ |
| Route | Intravenous | “A single infusion of BCMA CAR-T cells will be administered intravenously.” NCT04272151 ↗ |